论文部分内容阅读
目的观察利妥昔单抗(美罗华)联合CHOP方案治疗非霍奇金淋巴瘤的疗效及毒副反应。方法 9例经病理组织学证实为CD20阳性的B细胞非霍奇金淋巴瘤患者接受利妥昔单抗375mg/m2,静脉滴注,每3周1次,共4～6次。其间联用CHOP方案治疗4～6个疗程。结果 9例患者治疗后,完全缓解6例,部分缓解2例,无变化1例,总有效率88.9%。所有患者均未见严重的不良反应。结论利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤临床疗效较好,毒副反应较小。
Objective To observe the efficacy and side effects of rituximab (rituximab) combined with CHOP regimen in the treatment of non-Hodgkin’s lymphoma. Methods Nine patients with CD20-positive B-cell non-Hodgkin’s lymphoma confirmed by histopathology were treated with rituximab 375mg / m2 intravenously once every 3 weeks for 4 ~ 6 times. During the course of treatment with CHOP 4 to 6 courses. Results After treatment, 6 patients were completely relieved and 2 patients partially relieved. There was no change in 1 patient and the total effective rate was 88.9%. No serious adverse reactions were seen in all patients. Conclusions Rituximab combined with CHOP regimen is effective in treating B-cell non-Hodgkin’s lymphoma with less toxic and side effects.